Alice Tsang Shaw, MD, PhD, is a thoracic oncologist at the Massachusetts General Hospital Cancer Center.
- Centers & Specialties
- Clinical Interests
- Lung cancer treatment
- Medical Education
- MD, Harvard Medical School
- PhD, Harvard University
- Residency, Massachusetts General Hospital
- Fellowship, Dana Farber Cancer Institute
- Board Certifications
- Medical Oncology
- Boston: Massachusetts General Hospital
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- Cigna (PAL #'s)
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- Neighborhood Health Plan - ACD
- Neighborhood Health Plan - PBO
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- Private Health Care Systems (PHCS)
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Patient Age Group
Alice T. Shaw, MD, PhD, is an attending physician in the Center for Thoracic Cancers at Massachusetts General Hospital and an associate professor of medicine at Harvard Medical School. In addition to caring for patients with lung cancer, Dr. Shaw also performs clinical and translational research.
Dr. Shaw's major research interests include studying anaplastic lymphoma kinase (ALK) and ROS1 rearrangements in non-small cell lung carcinoma (NSCLC). She is also studying how lung cancers develop resistance to targeted therapies, and this work has led to a number of novel treatment strategies to overcome resistance in the clinic. Dr Shaw has been awarded a number of research grants, including grants from the Damon Runyon Cancer Research Foundation, the Burroughs Welcome Fund, the V Foundation for Cancer Research, Uniting Against Lung Cancer, the National Foundation for Cancer Research, and the NIH/NCI.
In a study examining the evolution of drug resistance in a lung cancer patient treated with multiple different targeted therapies, MGH physicians report that a new mutation conferring resistance to a next-generation targeted therapy actually restored the cancer's response to the very first targeted therapy drug used to treat the patient.
Treatment with the targeted therapy drug crizotinib effectively halts the growth of lung tumors driven by rearrangements of the ROS1 gene
A new drug called ceritinib appears to be effective against advanced ALK-positive non-small cell lung cancer, both in tumors that have become resistant to crizotinib and in those never treated with the older drug.
Research teams led by Massachusetts General Hospital (MGH) Cancer Center investigators are publishing two important studies regarding use of the targeted cancer drug crizotinib for treatment of advanced lung cancer driven by specific genetic mutations.
The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer.
MGH Cancer Center investigators have defined the role of a recently identified gene abnormality – rearrangements in the ROS1 gene – in non-small-cell lung cancer, the leading cause of cancer death in the U.S. They also show that these tumors can be treated with crizotinib and describe the remarkable response of one patient to such treatment.
Alice Shaw, MD, explains why patients with lung cancer can benefit from genetic testing
Alice Shaw, MD, thoracic oncologist at the Mass General Cancer Center, says patients with lung cancer can benefit from genetic testing, particularly if they are young non-smokers. Learn more about personalized treatment for lung cancer and new "smart drugs" that target a tumor's specific genetic mutation to slow the cancer's growth, and in some cases, reduce it significantly.
55 Fruit Street
Boston MA, 02114-2696
Phone 1: 617-724-4000